Prolonged, Low-Dose Anti-Thymocyte Globulin, Combined with CTLA4-Ig, Promotes Engraftment in a Stringent Transplant Model by D’Addio, Francesca et al.
 
Prolonged, Low-Dose Anti-Thymocyte Globulin, Combined with
CTLA4-Ig, Promotes Engraftment in a Stringent Transplant Model
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation D’Addio, Francesca, Olaf Boenisch, Ciara N. Magee, Melissa Y.
Yeung, Xueli Yuan, Bechara Mfarrej, Andrea Vergani,
Mohammed Javeed Ansari, Paolo Fiorina, and Nader Najafian.
2013. Prolonged, low-dose anti-thymocyte globulin, combined
with CTLA4-Ig, promotes engraftment in a stringent transplant
model. PLoS ONE 8(1): e53797.
Published Version doi:10.1371/journal.pone.0053797
Accessed February 19, 2015 11:57:00 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10665228
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAProlonged, Low-Dose Anti-Thymocyte Globulin,




1., Ciara N. Magee









1Renal Division, Transplantation Research Center, Brigham and Women’s Hospital and Children’s Hospital Boston, Harvard Medical School, Boston, Massachusetts, United
States of America, 2Transplantation Medicine Division, San Raffaele Hospital, Milan, Italy, 3Divisions of Nephrology and Organ Transplantation, Northwestern University
Feinberg School of Medicine, Chicago, Illinois, United States of America
Abstract
Background: Despite significant nephrotoxicity, calcineurin inhibitors (CNIs) remain the cornerstone of immunosuppression
in solid organ transplantation. We, along with others, have reported tolerogenic properties of anti-thymocyte globulin (ATG,
ThymoglobulinH), evinced by its ability both to spare Tregs from depletion in vivo and, when administered at low, non-
depleting doses, to expand Tregs ex vivo. Clinical trials investigating B7/CD28 blockade (LEA29Y, Belatacept) in kidney
transplant recipients have proven that the replacement of toxic CNI use is feasible in selected populations.
Methods: Rabbit polyclonal anti-murine thymocyte globulin (mATG) was administered as induction and/or prolonged, low-
dose therapy, in combination with CTLA4-Ig, in a stringent, fully MHC-mismatched murine skin transplant model to assess
graft survival and mechanisms of action.
Results: Prolonged, low-dose mATG, combined with CTLA4-Ig, effectively promotes engraftment in a stringent transplant
model. Our data demonstrate that mATG achieves graft acceptance primarily by promoting Tregs, while CTLA4-Ig enhances
mATG function by limiting activation of the effector T cell pool in the early stages of treatment, and by inhibiting
production of anti-rabbit antibodies in the maintenance phase, thereby promoting regulation of alloreactivity.
Conclusion: These data provide the rationale for development of novel, CNI-free clinical protocols in human transplant
recipients.
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Introduction
The introduction of calcineurin inhibitors (CNIs) into clinical
use positively influenced short-term graft survival by reducing
acute rejection rates [1]. CNI-containing immunosuppressive
regimens are, however, associated with significant morbidity,
including infection and neoplasia, whilst CNI-induced nephrotox-
icity remains a major barrier to long-term renal allograft survival,
and the most common cause of end-stage renal disease in
recipients of other solid organ transplants [2,3]. The achievement
of a state of selective hyporesponsiveness towards donor alloan-
tigens whilst maintaining recipient immunocompetence is, there-
fore, a major goal in clinical transplantation.
The alloimmune response is a complex interplay between
pathogenic/inflammatory and regulatory/anti-inflammatory im-
mune mechanisms; the supremacy of either process determines
whether the ultimate fate of the allograft is rejection or tolerance,
respectively [4–6]. Previous studies in renal transplant patients
demonstrated that Tregs regulate the alloimmune response and
contribute to alloantigen hyporesponsiveness [7,8]. Various
compounds, including ThymoglobulinH, alemtuzumab and siroli-
mus, are capable of inducing and expanding Tregs in vitro, both in
animals and humans [9–13]. The administration of standard,
depleting doses of murine homologue of polyclonal antithymocyte
globulin, mATG, has recently been shown to promote the
generation of Tregs capable of significant suppression both in vitro
and in a graft-versus-host disease (GVHD) model [14], and to
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diabetes [15,16]. Our group first reported that low, non-depleting
doses of ThymoglobulinH could expand human Tregs in vitro
[11,14,17], findings confirmed in a kidney transplant study where
treatment with low-dose ATG was associated with increased Tregs
and donor hyporesponsiveness [18]. We have, furthermore,
recently reported that this expansion is dependent on both intact
STAT-3 signalling in CD4
+ T cells and the presence of monocytes
[19]; indeed, the addition of ATG to purified CD4
+ T cells fails to
induce any Treg expansion [19,20].
Preclinical studies demonstrated that B7/CD28 costimulation
blockade with CTLA4-Ig effectively inhibits CD4
+ T cell
activation, proliferation and peripheral acquisition of an effector-
memory phenotype, thereby reducing graft rejection [21]. Indeed,
the recent clinical trials [22–25] and FDA approval of a mutant
form of CTLA4-Ig (LAE29Y/Belatacept) in human kidney
transplantation emphasizes the progression of B7/CD28 costim-
ulation blockade as an immunosuppressive strategy which could
avoid CNI toxicity.
We sought to develop a rational preclinical strategy to achieve
long-term allograft survival by limiting T cell alloreactivity and
expanding Tregs in vivo. We utilized a stringent, fully MHC-
mismatched murine model of skin transplantation, in which,
similar to human transplantation, graft acceptance has been
challenging to obtain.
Results
A Short Course of CTLA4-Ig with Prolonged, Low-dose
and Induction mATG Achieves Long-term Graft Survival
In a fully MHC-mismatched skin transplant model, mATG
induction (i-mATG; 0.5 mg on days 0 and 4 post-transplantation)
alone moderately prolonged allograft survival compared with
control Ig, an effect also seen with prolonged, low-dose mATG
(pld-mATG; 0.1 mg 2x/week) monotherapy (Figure 1A). The
addition of pld-mATG to the i-mATG protocol, however,
significantly enhanced graft survival (Figure 1A). While allograft
survival was modestly prolonged by a short course of CTLA4-Ig
monotherapy (0.5 mg on day 0, 0.25 mg on days 2, 4, 6, 8 and
10), significant enhancement was seen when CTLA4-Ig was
administered with i-mATG (MST=36 vs 15.5 days with i-mATG
alone, p=0.0035; Figure 1B). Intriguingly, animals treated with i-
mATG plus a short course of CTLA4-Ig with pld-mATG
(continued until day 90) demonstrated long-term graft survival,
as shown in Figure 1B and C (MST=119 days). Continued
administration of low-dose mATG after day 90 slightly improved
allograft survival (MST=130 days, p=0.23), but rejection
ultimately ensued.
Prolonged, Low-dose mATG Favors the Emergence of
Tregs
We examined the extent of T cell subset (CD4
+ and CD8
+)
depletion in both spleens and draining lymph nodes (dLN, not
shown, similar to spleens) in each of the treatment groups by flow
cytometry 7–10 days post-transplantation. As expected, i-mATG
resulted in near-complete depletion of CD4
+ (.85%) and CD8
+
(.95%) T cells, while pld-mATG caused some depletion of total
CD8
+, but no significant depletion of CD4
+ T cells compared to
naı ¨ve controls (Figure 1D–E). Furthermore, Tregs were spared
from depletion by i-mATG therapy, while pld-mATG expanded
Tregs compared to controls (Figure 1F). CTLA4-Ig did not affect
the frequencies of any of the above T cell subsets. Mice treated
with i-mATG+CTLA4-Ig+pld-mATG showed complete suppres-
sion of both CD4
+ and CD8
+ cells compared to controls
(Figure 2A–B); repeated enumeration revealed persistent, albeit
partial, T cell suppression until the cessation of pld-mATG at day
90, where upon both CD4
+ and CD8
+ T cell counts started to
recover, precipitating rejection (Figure 1B, 2A–B).
Prolonged Graft Survival is Achieved by Inhibition of
Effector T cells and Alloreactive IFNc Secretion
We next measured the frequency of overall T effector cells (Teff;
defined as CD44
hiCD62L
low) by flow cytometry, and of donor-
specific alloreactive IFNc-producing splenocytes by Elispot, in the
spleens and dLN (not shown, but similar to spleens) of different
treatment groups at various timepoints post-transplantation. At 7
days post-transplant, mice treated with i-mATG+CTLA4-Ig+pld-
mATG demonstrated a significant decrease in Teff compared to
controls (Figure 2C–D), while those treated with pld-mATG
maintained a CD8
+Teff count within the range expected for naı ¨ve
mice (Figure 2D), indicating that the observed total CD8
+ T cell
depletion (Figure 2B) was mainly due to the elimination of naı ¨ve T
cells. Although both CD4
+ and CD8
+ Teff counts rose from day
14 in the i-mATG+pld-mATG group, eventually contributing to
rejection, Teff were suppressed throughout the treatment course in
the i-mATG+CTLA4-Ig+pld-mATG-treated group, suggesting a
synergistic role of CTLA4-Ig in limiting their expansion over time.
The cessation of pld-mATG on day 90 was associated with a
progressive rise in both CD4
+ and CD8
+ Teff until rejection
occurred (Figure 2C–D). Similarly, donor-specific alloreactive
IFNc production was completely suppressed in the i-mATG+C-
TLA4-Ig+pld-mATG-treated group as long as pld-mATG was
administered (until day 90), but increased thereafter, accompanied
by the recovery of Teff (Figure 2E).
Treatment with i-mATG+CTLA4-Ig+pld-mATG Favors the
Emergence of Tregs
Effector T cell suppression may be achieved by directly affecting
Teff, and/or result indirectly from the promotion of Tregs, which
inhibit Teff. We therefore next tested the effects of our novel
immunomodulatory regimen on Tregs. Samples from dLN (not
shown) and spleens from each of the treatment groups were
stained for Tregs (CD4
+CD25
+FoxP3
+) 7, 14, 28, 42, 90, and 98
days post-transplantation. In the i-mATG+CTLA4-Ig+pld-mATG
group, absolute Treg counts steadily increased until their peak at
day 90, whereupon pld-mATG was withdrawn; numbers slowly
declined thereafter until rejection ensued (Figure 2F). Using the
absolute Treg and CD4
+ T cell counts at different timepoints, we
calculated the Tregs/CD4
+ ratio (Figure 2G–I), demonstrating a
significant increase in the proportion of Tregs over time in the i-
mATG+CTLA4-Ig+pld-mATG-treated group until day 90
(Figure 2I; 0.3860.01), following which it declined, leading to
rejection. These data highlight that the achievement of long-term
graft survival is associated with tipping the balance of T cell subsets
in favor of Tregs.
Skin Allograft Acceptance Requires the Expansion of Host
Natural Tregs (nTregs) by pld-mATG
We first evaluated the role of nTregs in long-term allograft
survival by investigating the effect of their depletion with anti-
CD25 antibody prior to skin transplantation. In control (not
shown) and CTLA4-Ig-treated groups, CD25
+ cell depletion did
not affect graft survival (Figure 3A). In contrast, CD25
+ cell
depletion was associated with significant abrogation of graft
survival in mice treated with pld-mATG alone, and particularly
those treated with i-mATG+CTLA4-Ig+pld-mATG (Figure 3B–
C). Intriguingly, the graft survival achieved following CD25
+ cell
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similar to that achieved by i-mATG+CTLA4-Ig in the presence
of CD25
+ cells but without pld-mATG (MST=40 vs 44 days,
p=0.61), suggesting that the removal of either pld-mATG or
nTregs from the protocol has the same effect.
To specifically and directly confirm the role of mATG in nTreg
expansion, we studied the effect of mATG therapy or control Ig on
allospecific Tregs using an adoptive transfer model. In brief, this is
a Thy1.2
+B6 TCR-tg mouse with CD4
+ T cells that express a




+ABM-tg T cells are adoptively
transferred into congenic WT Thy1.1
+B6 mice that simultaneous-
ly receive a bm12 skin transplant, and are treated with either
mATG or control Ig; allospecific cells can then be tracked by the
cell surface marker Thy1.2 (CD90.2). The mATG-treated group
showed significant expansion of Thy1.2
+FoxP3GFP
+ cells com-
pared to controls (p=0.039, Figure 3D).
i-mATG+pld-mATG+prolonged CTLA4-Ig Induces Very-
long-term Graft Survival, an Effect Primarily Due to pld-
mATG
As the combination of i-mATG, pld-mATG and a short course
of CTLA4-Ig achieved long-term graft survival, but not tolerance,
we next tested the effect of a prolonged course of CTLA4-Ig
(pCTLA4-Ig; 0.25 mg 2x/week) in addition to pld-mATG and i-
mATG in our stringent skin transplant model. We administered i-
mATG and pld-mATG as described, but continued to administer
CTLA4-Ig until day 90, whereupon mice were randomized to 3
treatment groups: one group stopped both drugs (no treatment
after day 90), another continued only with CTLA4-Ig (random-
ization CTLA4-Ig), while the last continued with pld-mATG only
(randomization pld-mATG). The addition of pCTLA4-Ig to the
previous regimen increased graft survival to some degree, although
rejection ultimately ensued following the cessation of both drugs
on day 90 (MST=134 vs 119 days, p=0.003). Intriguingly, the
group randomized to continue with CTLA4-Ig alone did not
display any further prolongation of graft survival compared to the
group in which both treatments were stopped (MST=135 vs 134
days, p=0.595). However, the grafts of those animals randomized
to continue with pld-mATG survived more than 200 days
(p,0.0001; Figure 4A), but ultimately rejected (MST=218 days).
Flow cytometry analysis of dLN (not shown) and spleens on days
90, 120, and 135 demonstrated persistent CD4
+ and CD8
+ cell
suppression in mice randomized to continue with pld-mATG,
while in those randomized to continue with CTLA4-Ig alone, or
where both drugs were stopped on day 90, T cell subsets increased
until rejection occurred (Figure 4B–C). Similarly, levels of both
CD4
+ and CD8
+ Teff remained low in the group randomized to
continue with pld-mATG, but increased immediately in the other
groups following the cessation of mATG on day 90 (Figure 5A–B).
Donor-specific alloreactive IFNc production was completely
inhibited by the extended administration of pld-mATG, while
the cessation of both drugs on day 90 or randomization to
continued CTLA4-Ig alone was associated with a gradual rise in
IFNc production, until rejection ensued (Figure 5C).
Day 90 Randomization to pld-mATG Enhances Graft
Survival by Favoring Persistent Treg Emergence
We demonstrated a persistent increase in Tregs in animals
randomized to continue with pld-mATG beyond day 90, while in
Figure 1. Prolonged, low-dose mATG with a short course of CTLA4-Ig and induction mATG achieves long-term graft survival and
favors the emergence of Tregs. A. Kaplan-Meier graph depicting fully MHC-mismatched skin allograft survival following the administration of
pld-mATG, i-mATG, i-mATG plus pld-mATG, or no treatment. B. Kaplan-Meier graphs depicting fully MHC-mismatched skin allograft survival in mice
administered i-mATG alone, CTLA4-Ig alone,CTLA4-Ig in combination with i-mATG with/without pld-mATG, or no treatment. C. Representative
pictures of skin graft from untreated (left panel) and i-mATG plus CTLA4-Ig and pld-mATG-treated mice (right panel). D/E. Bar graphs depicting
absolute numbers of CD4
+ and CD8
+ cells 7–10 days post-transplantation in mice administered either i-mATG, pld-mATG, CTLA4-Ig or no treatment.
F. Bar graphs depicting absolute numbers of CD4
+CD25
+FoxP3
+ cells (Tregs) 7–10 days post-transplantation in mice administered either i-mATG, pld-
mATG, CTLA4-Ig or no treatment. Data are representative of $3 independent experiments using $3 mice per group per timepoint studied.
doi:10.1371/journal.pone.0053797.g001
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significant decline following the cessation of pld-mATG at day 90
(Figure 5D). Calculation of the Tregs/CD4
+ ratio demonstrated
persistent emergence of the proportion of Tregs when pld-mATG
was continued, while in animals randomized to continue with
CTLA4-Ig alone, there was a remarkable decline in the proportion
of Tregs within the overall CD4
+ subset (Figure 5E–F). These
results confirm that the long-term graft acceptance achieved in the
pld-mATG-randomized group is mainly due to the promotion of
Tregs within the CD4
+ population, resulting in an increased Treg/
CD4
+ cell ratio, tipping the balance of the alloimmune response
towards regulation.
CTLA4-Ig Inhibits Production of Anti-rabbit Antibodies,
Allowing Unimpeded mATG Function
While randomization to pCTLA4-Ig alone on day 90 did not
further enhance allograft survival, continued administration of pld-
mATG after day 90 achieved very-long-term graft survival,
although grafts were ultimately rejected (MST=218 days). We
then investigated the effect of extended co-administration of pld-
mATG and pCTLA4-Ig on allograft survival, and observed
indefinite graft acceptance as long as both drugs were adminis-
tered.
To explore these observations, we investigated if mATG
function was eventually affected by the production of anti-rabbit
IgG antibodies, considering its prolonged and repetitive admin-
istration. We observed high titers of mouse anti-rabbit antibodies
in the i-mATG+pld-mATG-treated group (656100 vs ,100 in
naı ¨ve serum), confirming that chronic exposure to mATG induces
an antibody response. Critically, the addition of either a short or
prolonged course of CTLA4-Ig effectively prevented the develop-
ment of anti-rabbit antibodies (,100 on day 90 and 120). Indeed,
cessation of CTLA4-Ig on day 90 and randomization to extended
treatment with pld-mATG alone resulted in a high level of
antibody production over time (8100 vs ,100 in naı ¨ve serum on
day 180) and, ultimately, rejection. The essential role of CTLA4-
Ig in preventing antibody production was further evinced by the
extended co-administration of pld-mATG and pCTLA4-Ig
Figure 2. Prolonged graft survival is achieved by inhibiting effector T cells/alloreactive IFNc secretion and by favoring the
emergence of Tregs. A/B. Graphs demonstrating absolute numbers of CD4
+ and CD8
+ T cells with various treatment strategies. C/D. Frequency of
Teff cells (CD4
+/CD8
+) using calculated absolute numbers at different timepoints in various treatment groups. E. Comparison of donor alloreactive
IFNc production at different timepoints after fully MHC-mismatched skin transplantation in animals administered various treatment protocols. F.
Absolute numbers of Tregs at different time points in mice treated with i-mATG, CTLA4-Ig plus pld-mATG. G/H/I. Dot plots representing Tregs/CD4+
ratios in mice treated with pld-mATG alone, i-mATG plus pld-mATGor i-mATG combined with CTLA4-Ig plus pld-mATG during the transplant course.
Data are representative of $3 independent experiments using $3 mice per group per timepoint studied.
doi:10.1371/journal.pone.0053797.g002
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absence of anti-rabbit antibodies (,100 on day 180).
Combined Treatment with pld-mATG and CTLA4-Ig does
not Inhibit Nominal Antigen Recall Response
Following immunization with ovalbumin (OVA), mice under-
went transplantation and either received no treatment or were
treated with pld-mATG+CTLA4-Ig for 14 days, whereupon
splenocytes were collected and challenged in vitro with OVA in an
IFNc Elispot assay. While the number of IFNc-producing cells
increased slightly in the untreated versus treated mice in response
to OVA re-stimulation, this did not reach statistical significance
(immunized during treatment=368649 vs immunized untreat-
ed=462616 spots, n=3, p=0.06), indicating that, despite pld-
mATG+CTLA4-Ig treatment, the mice remained capable of a
nominal antigen recall response.
Discussion
The tissue toxicity and vascular injury associated with CNI use,
in addition to inadequate control of the alloimmune response, are
thought to be major barriers to the achievement of long-term graft
survival in transplantation. Therefore, the development of
strategies to promote allograft survival whilst eliminating the
requirement for CNIs, and/or to induce allograft tolerance, have
become a major goal in the transplant community [2,24,26,27].
Potential approaches include deletion of peripheral alloreactive
effector T cells with induction therapy, inhibition of T cell
activation by costimulatory blockade, and promotion of active
regulation by harnessing the regulatory potential of Tregs [4,6,26].
T cell depleting antibodies successfully prevent acute rejection
immediately after transplantation, but recipients ultimately devel-
op subacute or chronic rejection [2,28]: despite near-complete
naı ¨ve T cell depletion, a small fraction of T cells are capable of
Figure 3. Skin allograft acceptance requires the expansion of host natural Tregs (nTregs) by prolonged, low-dose mATG. A/B/C.
Kaplan-Meier graphs depicting fully MHC-mismatched skin allograft survival with or without CD25
+ cell depletion in mice treated with CTLA4-Ig alone
(A), pld-mATG alone (B) or i-mATG, CTLA4-Ig plus pld-mATG (C). D. Bar graphs depicting absolute numbers of Thy1.2
+FoxP3GFP
+ cells in untreated
and mATG-treated groups on day 7. Representative histograms of Thy1.2
+FoxP3GFP
+ cells from recipients in each treatment group are shown below
the respective bar graphs.
doi:10.1371/journal.pone.0053797.g003
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phenotype, undergo homeostatic proliferation and mediate graft
rejection [29]. This highlights the necessity of inhibiting homeo-
static proliferation of the remaining T cells to establish regulation,
wherein two possible strategies have been shown to be effective:
costimulation blockade [30–32] and Treg exploitation [33]. ATG,
long used as a T cell depleting therapy, has more recently been
investigated for its potential to expand human Tregs; indeed, our
group was the first to report that the addition of low, non-depleting
doses of Thymoglobulin
H to peripheral blood mononuclear cells
(PBMCs) could expand human Tregs in vitro [11]. These findings
were subsequently challenged by a Canadian study that failed to
demonstrate any such expansion using isolated CD4
+ cells [20].
The use of purified CD4
+ T cells by the Canadian group is,
however, a critical point, as we have recently shown that the in vitro
expansion of human Tregs by ATG is dependent both on intact
STAT-3 signalling in CD4
+ T cells and the presence of monocytes
[19].
Further insights gained from review of the referenced studies
formed the rationale to develop a novel therapeutic protocol
consisting of T cell-depleting induction, costimulatory blockade
with CTLA4-Ig, and prolonged, low-dose ATG. We utilized a
stringent, fully MHC-mismatched skin transplant model, where
tolerance is difficult to achieve unless released from thymic
influence, rendering the continuous restraint of alloreactive
effector cells by Tregs essential. In our study, we first utilized
mATG as induction therapy (i-mATG), obtaining near-complete
T cell depletion whilst sparing Tregs, as previously demonstrated.
We then reduced the dose to 20% of that used for induction and
administered this for a prolonged period (pld-ATG), demonstrat-
ing that, in contrast to naı ¨ve mice, this regimen did not suppress
the overall CD4
+ T cell count but did deplete CD8
+ T cells,
although to a significantly lesser extent than the induction dose,
and mainly by eliminating the naı ¨ve CD8
+ T cell subset. Crucially,
however, pld-mATG significantly expanded Tregs in both the
spleen and dLN, and in our adoptive transfer model utilizing
FoxP3GFP-ABM mice, expanded alloreactive nTregs. Further-
more, depletion of nTregs abrogated the graft prolongation
achieved by the pld-mATG regimen. In aggregate, these data
establish the ability of pld-mATG to improve allograft survival by
expanding nTregs without significant T cell depletion.
Similarly, the regimen consisting of i-mATG, pld-mATG and a
short course of CTLA4-Ig significantly enhanced allograft survival
and suppressed effector T cells and the Th1 response over time.
Both the absolute number of Tregs and proportion of Tregs within
the T cell compartment rose progressively during treatment,
thereby tipping the balance in favor of Tregs. Prior Treg depletion
and cessation of treatment with pld-mATG, but not CTLA4-Ig,
Figure 4. Treatment with i-mATG+pld-mATG+prolonged CTLA4-Ig induces very-long-term graft survival, an effect primarily due to
pld-mATG. A. Skin allograft survival in mice treated with i-mATG, pCTLA4-Ig plus pld-mATG: on day 90 mice were randomized either to cessation of
both treatments or to extended treatment with CTLA4-Ig or pld-mATG alone. B/C. Absolute numbers of CD4
+/CD8
+ cells at different timepoints post-
transplantation in mice treated with i-mATG with pCTLA4-Ig and pld-mATG until day 90 and thereafter randomized to pld-mATG or CTLA4-Ig alone or
no further treatment. Data are representative of $3 independent experiments using $3 mice per group per timepoint studied.
doi:10.1371/journal.pone.0053797.g004
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survival in mATG-based treatment groups, suggesting an impor-
tant role for continuous, low-dose mATG in promoting regulation.
These data agree with recent studies by Nador and colleagues,
demonstrating the promotion of Tregs by antithymocyte serum in
a mixed chimerism tolerance model following combined heart and
bone marrow transplantation [34], and by Vergani et al, showing
improved allograft survival in an islet transplantation model [16].
Our data with OVA immunization emphasize that the combina-
tion of pld-mATG and CTLA4-Ig preserves the nominal antigen
recall response of the recipient whilst inducing alloantigen-specific
hyporesponsiveness.
Finally, the production of mouse anti-rabbit-antibodies was
suppressed in combination treatments with CTLA4-Ig, but
significantly increased when pld-mATG was administered alone
or continued following the cessation of CTLA4-Ig, confirming that
CTLA4-Ig inhibits antibody production against rabbit Ig,
permitting unimpeded mATG function. This was confirmed by
the achievement of very-long-term allograft survival so long as
both pCTLA4-Ig and pld-mATG were given concurrently, and by
the absence of anti-rabbit antibodies in these mice.
In summary, this study demonstrates that prolonged, low-dose
mATG primarily inhibits alloreactive T cells by expanding Tregs,
while CTLA4-Ig enhances mATG function by limiting activation
of the effector T cell pool in the early stages of treatment, and by
inhibiting production of anti-rabbit antibodies in the maintenance
phase, thereby promoting regulation of alloreactivity. The
combination of prolonged, non-depleting mATG and CTLA4-Ig




C57BL/6 (B6, H-2b), BALB/c (H-2d) and B6.PL-Thy1
a/CyJ
(Thy1.1 B6) mice were purchased from The Jackson Laboratory.
Thy1.2 FoxP3GFP-ABM TCR-tg mice were generated by
breeding FoxP3GFP reporter mice with ABM (anti-bm12) TCR-
tg mice which have a TCR that specifically recognizes the MHC
class II molecule I-A
bm12; both parent strains have the C57BL/6
background and bear the Thy 1.2 allele. All mice were used at 6–
12 weeks of age.
Ethic Statement
Mice were housed in accordance with Harvard Medical Area
Standing Committee on Animals (HMA IACUC) approval. All the
experimental procedures were performed in accordance with
Institutional and National Institutes of Health guidelines and
Harvard Medical Area Standing Committee on Animals (HMA
IACUC) approval. The study was carried out in strict accordance
Figure 5. Day 90 randomization to pld-mATG enhances graft survival by favoring persistent Treg emergence. A/B. Frequency of CD4
+/
CD8
+ effector T cells at different timepoints in mice treated with i-mATG, pCTLA4-Ig plus pld-mATG until day 90 and thereafter randomized to
extended pld-mATG or CTLA4-Ig or no further treatment. C. Alloreactive IFNc production at different timepoints in mice treated with i-mATG,
pCTLA4-Ig plus pld-mATG until day 90 and thereafter randomized to extended pld-mATG or CTLA4-Ig or no further treatment. D. Absolute numbers
of Tregs at different timepoints in skin transplant recipients randomized at day 90 to either extended pld-mATG or CTLA4-Ig or no further treatment.
E/F. Treg/CD4
+ratios at different timepoints after transplantation in mice treated with i-mATG, pCTLA4-Ig plus pld-mATG until day 90, and thereafter
randomized to extended pld-mATG or CTLA4-Ig alone. Data are representative of $3 independent experiments using $3 mice per group per
timepoint studied.
doi:10.1371/journal.pone.0053797.g005
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Laboratory Animals of the National Institutes of Health. All
surgery was performed using CO2 overdose euthanasia, consistent
with the recommendations of the American Veterinary Medical
Association in accordance with Institutional HMA IACUC
approval and all efforts were made to minimize suffering.
Generation and Characterization of mATG
Murine anti-thymocyte globulin (mATG) was generated in a
manner analogous to the commercial ATG product (Thymoglo-
bulinH) by immunizing rabbits with a mixture of thymocytes from
8 different strains of mice (C57BL/6, BALB/c, DBA/2, 129,
C3H, SJL, Swiss Webster, ICR), as described [9,35]. Control
rabbit IgG was either similarly purified from whole normal rabbit
serum or obtained commercially (Sigma, St. Louis, MO).
Skin Transplantation
Full-thickness trunk skin grafts (1 cm
2) from BALB/c donors
were transplanted onto the flank of B6 recipient mice, sutured with
6.0 silk, and secured with dry gauze and a bandage for 7 days. Skin
graft survival was monitored daily thereafter, and rejection defined
as complete graft necrosis.
Treatment Protocols
mATG was administered as induction therapy (i-mATG) at a
dose of 0.5 mg on days 0 and 4 post-transplantation; prolonged,
low-dose mATG (pld-mATG) treatment consisted of 0.1 mg
injected twice a week (2x/week). CTLA4-Ig (Abatacept) was
obtained from Bristol-Myers Squibb; the short course consisted of
0.5 mg on day 0 and 0.25 mg on days 2, 4, 6, 8 and 10, while
prolonged administration (pCTLA4-Ig) consisted of 0.25 mg 2x/
week. CD25
+ T cell depletion was achieved by treating mice with
0.5mg of anti-CD25 mAb (PC61) on days 6 and 1 pre-
transplantation. All treatments were administered by intraperito-
neal injection.
Flow Cytometry
Recipient lymphocytes were isolated from the spleens and
draining lymph nodes at various timepoints post-transplantation.
Cells were stained with anti-CD3 FITC, anti-CD8 APC, and anti-
CD4 PerCP to assess T cell depletion; effector T cells were
identified by staining with anti-CD4 PerCP, anti-CD8 FITC, anti-
CD62L APC, and anti-CD44 PE (all BD Pharmingen), and
analyzed for cells bearing the CD44
hiCD62L
low phenotype. Tregs
were identified by staining with anti-CD4 FITC and anti-CD25
PE, followed by intracellular staining with FoxP3 APC
(eBioscience), as per the manufacturer’s instructions.
Transgenic Experiment
Spleens and lymph nodes were harvested from Thy1.2
+-
FoxP3GFP-ABM mice; pooled single-cell leukocyte suspensions
were prepared. CD4
+ T cells were purified by negative selection
(Miltenyi Biotec, Auburn, CA), achieving.90% purity. An aliquot
of cells was stained with anti-CD4, anti-TCR Va2.1, and anti-
TCR Vb8.1, 8.2, and analyzed by flow cytometry to determine the
percentage of ABM TCR-tg CD4
+ T cells. Typically, .90% of
CD4
+ T cells expressed the tg TCR, and 2% of CD4
+ T cells were
determined to be GFP
+. CD4
+ isolated cells were then flow-sorted
for GFP
+/2 cells achieving a purity of 97%. 0.3610
6 Thy1.2
+-
FoxP3GFP-positive cells were injected intraperitoneally into
Thy1.1
+B6 mice that received a bm12 skin graft and either
mATG or control Ig, according to the protocol. On day 7,
draining (axillary, lateral axillary) lymph nodes and spleens were
collected and Thy1.2
+FoxP3GFP
+ TCR-tg T cells enumerated in
both groups. To identify the adoptively transferred cells, 1610
6
naturally labelled gfp cells were stained with biotinylated Thy1.2
(CD901.2), followed by APC-conjugated Streptavidin. To confirm
the cells were indeed all tg, they were also stained with PerCP-
conjugated anti-CD4 and both APC-conjugated anti-TCR Va2.1
(B20.1) and PE-conjugated anti-TCR Vb8.1 (MR5-2).
ELISPOT Assay
Immunospot plates (Cellular Technology, Cleveland) were
coated with anti-mouse IFNc. Recipient splenocytes plus irradi-
ated (30Gy) allogeneic splenocytes (0.5610
6 each) were cultured
for 24h, incubated with biotinylated anti-mouse IFNc and
streptavidin horseradish peroxidase (DAKO), and developed with
3-amino-9-ethylcarbazole (Sigma-Aldrich). The resulting spots
were counted on a computer-assisted immunospot image analyzer
(T Spot Image Analyzer, Cellular Technology). All mAbs were
from BD Pharmingen.
Ovalbumin Immunization
Ovalbumin (Sigma Aldrich) emulsified in complete Freund’s
adjuvant (Sigma Aldrich) was injected once (100 mg/mouse i.p.) in
transplanted mice. Splenocytes were collected and used in vitro
following rechallenge with 1 mmol/l ovalbumin for 24h.
Serum Anti-rabbit IgG Titers
Anti-rabbit IgG titers were determined by a standard ELISA
procedure. Briefly, microtiter plates were coated with purified
rabbit IgG (Bethyl Labs), followed by incubation with serially
diluted mouse serum samples. Anti-rabbit antibodies in the serum
were detected with an HRP-conjugated goat anti-mouse IgG
antibody (Southern Biotech), followed by TMB substrate (BioFX)
for 15 minutes; the reaction was stopped with 1N HCL (VWR).
Titers were determined as the lowest dilution that averaged above
an absorbance of 0.100.
Statistics
Graft survival was expressed graphically by the Kaplan-Meier
method, and statistical differences between groups assessed by the
log-rank test. Student t test was used for comparison of means.
P,0.05 was considered statistically significant.
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